Brief: Citius Pharma's Unit To Merge With Tenx Keane Acquisition To Form Publicly Listed Citius Oncology
24/10/2023 13:40
Oct 24 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS EXECUTES DEFINITIVE AGREEMENT TO
MERGE
WHOLLY OWNED SUBSIDIARY WITH TENX KEANE ACQUISITION TO FORM
PUBLICLY LISTED CITIUS ONCOLOGY, INC.
* CITIUS PHARMACEUTICALS INC - PROPOSED DEAL FOR CITIUS
PHARMA
WOULD RECEIVE 67.5 MILLION SHARES IN CITIUS ONCOLOGY AT $10 PER
SHARE
* CITIUS PHARMACEUTICALS INC: TRANSACTION ANTICIPATED TO
CLOSE IN
FIRST HALF OF 2024
Source text for Eikon: ID:nGNX5G2vSv
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules